WO2023178169A3 - Compositions and methods for treating the pathophysiology of severe viral infection - Google Patents

Compositions and methods for treating the pathophysiology of severe viral infection Download PDF

Info

Publication number
WO2023178169A3
WO2023178169A3 PCT/US2023/064419 US2023064419W WO2023178169A3 WO 2023178169 A3 WO2023178169 A3 WO 2023178169A3 US 2023064419 W US2023064419 W US 2023064419W WO 2023178169 A3 WO2023178169 A3 WO 2023178169A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant
biologically active
pathophysiology
compositions
treating
Prior art date
Application number
PCT/US2023/064419
Other languages
French (fr)
Other versions
WO2023178169A2 (en
Inventor
Jian Qing XU
Robert Mandell
Beverly W. Lubit
Original Assignee
Anemoi Biotech Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anemoi Biotech Holdings, Inc. filed Critical Anemoi Biotech Holdings, Inc.
Publication of WO2023178169A2 publication Critical patent/WO2023178169A2/en
Publication of WO2023178169A3 publication Critical patent/WO2023178169A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

According to one aspect the described invention provides a method for reducing damaging effects of a severe virus infection in a susceptible subject comprising administering a pharmaceutical composition comprising a vehicle and a recombinant bifunctional fusion protein comprising a recombinant biologically active immunomodulatory component operatively linked to a recombinant biologically active anti-viral component, the recombinant immunomodulatory component comprising a recombinant biologically active human trefoil protein molecule, fragment or variant and the recombinant anti-viral component comprising a recombinant biologically active human interferon molecule, fragment or variant, wherein the method rescues symptoms of the severe virus infection.
PCT/US2023/064419 2022-03-15 2023-04-19 Compositions and methods for treating the pathophysiology of severe viral infection WO2023178169A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263320119P 2022-03-15 2022-03-15
US63/320,119 2022-03-15
US202263371303P 2022-08-12 2022-08-12
US63/371,303 2022-08-12

Publications (2)

Publication Number Publication Date
WO2023178169A2 WO2023178169A2 (en) 2023-09-21
WO2023178169A3 true WO2023178169A3 (en) 2023-11-23

Family

ID=88024394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/064419 WO2023178169A2 (en) 2022-03-15 2023-04-19 Compositions and methods for treating the pathophysiology of severe viral infection

Country Status (1)

Country Link
WO (1) WO2023178169A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202421A1 (en) * 2001-10-31 2005-09-15 Raphael Hirsch Method for diagnosis and treatment of rheumatoid arthritis
US7955590B2 (en) * 1999-07-21 2011-06-07 Merck Patent Gmbh Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20180200349A1 (en) * 2008-06-16 2018-07-19 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
US20190022169A1 (en) * 2011-04-12 2019-01-24 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US20210252142A1 (en) * 2020-02-06 2021-08-19 Aetio Biotherapy, Inc. Compositions and methods for treating viral infections
CN114853911A (en) * 2022-05-23 2022-08-05 复旦大学 Trefoil factor 2/interferon alpha 2 fusion protein and application thereof in preventing and treating virus infectious diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955590B2 (en) * 1999-07-21 2011-06-07 Merck Patent Gmbh Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20050202421A1 (en) * 2001-10-31 2005-09-15 Raphael Hirsch Method for diagnosis and treatment of rheumatoid arthritis
US20180200349A1 (en) * 2008-06-16 2018-07-19 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
US20190022169A1 (en) * 2011-04-12 2019-01-24 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US20210252142A1 (en) * 2020-02-06 2021-08-19 Aetio Biotherapy, Inc. Compositions and methods for treating viral infections
CN114853911A (en) * 2022-05-23 2022-08-05 复旦大学 Trefoil factor 2/interferon alpha 2 fusion protein and application thereof in preventing and treating virus infectious diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE Nucleotide 24 May 2023 (2023-05-24), ANONYMOUS : "Homo sapiens interferon kappa (IFNK), mRNA", XP093114041, retrieved from Genbank Database accession no. NM_020124 *
FU WEIHUI, LIU YAN, LIU LI, HU HUILIANG, CHENG XIAOBO, LIU PING, SONG ZHIGANG, ZHA LIJUN, BAI SHIMENG, XU TINGTING, YUAN SONGHUA, : "An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19", ECLINICAL MEDICINE, vol. 27, 1 October 2020 (2020-10-01), pages 1 - 11, XP093114026, ISSN: 2589-5370, DOI: 10.1016/j.eclinm.2020.100547 *
FU WEIHUI, LIU YAN, XIA LU, LI MIN, SONG ZHIGANG, HU HUILIANG, YANG ZONGGUO, WANG LIN, CHENG XIAOBO, WANG MEI, JIANG RONGRONG, LIU: "A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19", ECLINICAL MEDICINE, vol. 25, 1 August 2020 (2020-08-01), pages 1 - 8, XP093061102, ISSN: 2589-5370, DOI: 10.1016/j.eclinm.2020.100478 *
LIU YAN, ZHAI GUANXING, FU WEIHUI, ZHANG XIAOYAN, XU JIANQING: "A randomized, double-blind, placebo-controlled phase I trial of inhalation treatment of recombinant TFF2-IFN protein: A multifunctional candidate for the treatment of COVID-19", FRONTIERS IN PHARMACOLOGY, vol. 13, 1 January 2022 (2022-01-01), CH , pages 1 - 10, XP093114020, ISSN: 1663-9812, DOI: 10.3389/fphar.2022.1063106 *

Also Published As

Publication number Publication date
WO2023178169A2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US5503828A (en) Alpha interferon composition and method for its production from human peripheral blood leukocytes
EP0315968B2 (en) Plasma and recombinant protein formulations in low ionic strength media
KR100415636B1 (en) A pharmaceutical composition for the treatment of multiple sclerosis comprising interferon consensus and interleukin-1 receptor antagonist
US5725864A (en) Composition for suppressing infection and growth of human immunodeficiency virus
EP2097068B1 (en) Formulations of peg-interferon alpha conjugates
CA2073031A1 (en) Anti-cd4 antibody homologs useful in prophylaxis and treatment of aids, arc and hiv infection
RU94022480A (en) Method of hepatitis treatment, composition enhancing in vivo inactivation of hepatitis virus c, preparation for hepatitis c treatment
JP2008503207A5 (en)
WO1998052415B1 (en) Substantially pure zonulin, a physiological modulator of mammalian tight junctions
CA2380833A1 (en) Proteins derived from white spot syndrome virus and uses thereof
EP2117514A1 (en) Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
WO1998019670A3 (en) Combination therapy of hepatitis C infections
WO2023178169A3 (en) Compositions and methods for treating the pathophysiology of severe viral infection
Minagar et al. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF
CZ277712B6 (en) Mixture containing alpha-interferon
Stewart et al. Interferoids: In vitro and in vivo conversion of native interferons to lower molecular weight forms
CA2306441A1 (en) Peptides derived from the env gene of the feline immunodeficiency virus and their applications
KR960700741A (en) METHOD OF TREATING HEPATITIS C IN NON-PESPONDERS TO INTERFERON TREATMENT
EP1137433B1 (en) Pharmaceutical compositions containing protein-disulfide isomerases
EP3744319B1 (en) A stable lyophilized formulation for hybrid fc fused g-csf
WO2021239165A3 (en) Peptide for treating coronavirus infections
WO2024044663A3 (en) Peptide and nucleic acid methods to modulate delivery of nucleic acid structures, polypeptides, and their cargoes
CA3242034A1 (en) Pharmaceutical composition for treatment of viral infections
CENGİZ et al. POTENTIAL ANIMAL POISONS FOR DEVELOPMENT OF ANTIVIRAL THERAPEUTICS
WO2022115536A3 (en) Methods and compositions for treating viral infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23771625

Country of ref document: EP

Kind code of ref document: A2